Skin graft rejection occurs when a recipient’s immune system identifies transplanted skin as foreign tissue and mounts an attack against it, ultimately destroying the graft if left untreated. The process is driven primarily by T cells that recognize mismatched proteins on the donor tissue, and rejection rates in composite tissue transplants like hands and faces exceed 80 percent during the first few years after surgery. The topic is more layered than most people realize, because not all skin grafts carry the same risk, the immune response can take very different forms depending on timing, and the treatments involve tradeoffs that patients live with for decades.
Why the Body Attacks Transplanted Skin
Skin is one of the most immunogenic tissues in the body, meaning it provokes a stronger immune response than many other transplanted organs. The core reason is that skin cells display a dense collection of surface proteins that vary from person to person. When a graft carries proteins the recipient’s immune system has never seen, immune cells treat the tissue the way they would treat a dangerous invader. T cells are the primary drivers of this response. Both CD4+ and CD8+ T cells recognize foreign markers on the graft, infiltrate the tissue, and begin destroying it from within. Recurrent episodes of this T-cell-driven attack have been linked to long-term graft dysfunction and eventual loss of the transplanted tissue.1PubMed Central. An Immune Atlas of T Cells in Transplant Rejection: Pathways and Therapeutic Opportunities
A separate and sometimes overlapping pathway involves antibodies. When the recipient already has or develops antibodies against the donor’s tissue, those antibodies can trigger complement activation, a cascade of proteins that damages blood vessels within the graft. This antibody-mediated rejection is a particular concern because it tends to be resistant to the standard anti-rejection drugs that work well against T-cell attacks.2PubMed Central. Mechanisms involved in antibody- and complement-mediated allograft rejection In practice, many rejection episodes involve both pathways working in concert, which complicates treatment considerably.
How Tissue Matching Shapes the Odds
The proteins that trigger rejection belong to a family called HLA antigens. Everyone inherits a unique combination of these markers, and the closer a donor’s HLA profile matches the recipient’s, the less aggressive the immune response tends to be. In a landmark study of skin transplants, grafts exchanged between donor-recipient pairs matched for HLA-A, B, and DR antigens survived an average of 17 days, while completely mismatched grafts lasted only about 10 days.3PubMed. Influence of matching for HLA-DR antigens on skin graft survival That difference might sound modest in absolute terms, but in the context of skin grafting, where early vascularization needs to occur within days, a week of extra survival can determine whether a graft takes permanently or fails.
Perfect matching is rare outside of identical twins. For most patients receiving allografts (skin from another person), some degree of mismatch is unavoidable. This is why immunosuppressive drugs remain essential for anyone receiving donor skin. The matching data also helps explain why autografts, where the skin comes from the patient’s own body, avoid rejection entirely: the immune system recognizes its own HLA markers and leaves the tissue alone.
Three Timelines of Rejection
Rejection does not follow a single script. It can unfold over hours, days, or months, and each timeline involves somewhat different immune mechanisms and carries different consequences.
- Hyperacute rejection: This happens within minutes to hours after transplantation and is caused by pre-existing antibodies in the recipient’s blood that immediately bind to the graft’s blood vessels. Complement proteins pile on, blood flow is destroyed, and the graft dies rapidly. This form is rare in skin grafting because screening for pre-formed antibodies has improved, but it remains a risk when recipients have been sensitized by previous transfusions, pregnancies, or transplants.
- Acute rejection: The most common form, typically appearing within the first days to weeks. T cells infiltrate the graft and attack its cells directly. In hand and face transplants, acute rejection episodes occur in roughly two-thirds to three-quarters of patients despite ongoing immunosuppressive therapy.4PubMed Central. Immunosuppressive strategies in face and hand transplantation: a comprehensive systematic review of current therapy regimens and outcomes Acute episodes are treatable, but repeated bouts take a cumulative toll.
- Chronic rejection: A slow, insidious process that develops over months to years. Rather than the dramatic inflammation of acute rejection, chronic rejection is defined by progressive fibrosis, thickening of blood vessel walls, and gradual loss of normal skin structures like hair follicles and sweat glands. Research in animal models has shown that chronically rejected grafts display extensive collagen buildup throughout the dermis, along with vascular narrowing and mast cell infiltration.5PubMed Central. Chronic rejection models for vascularized composite tissue allotransplantation Chronic allograft vasculopathy, where the arteries feeding the graft become progressively narrower, is considered the leading cause of long-term graft failure across all types of transplants.
Recognizing the Signs
The visible signs of rejection depend on which timeline is playing out. Acute rejection typically shows up as redness, swelling, and a rash-like appearance on the grafted skin. The graft may become tender, develop small blisters, or take on a dusky, mottled color as blood flow is disrupted. In hand and face transplants, the skin of the graft can look sunburned or develop raised patches that feel warm to the touch. These signs tend to appear within the first week or two, though late acute episodes can surface months or even years later.
Chronic rejection looks different. Because it unfolds gradually, patients may notice progressive tightening or hardening of the grafted skin, thinning hair in the graft area, and a general loss of suppleness. The skin may feel leathery or contractured. These changes reflect the underlying fibrosis and vascular damage, and by the time they are noticeable, the process is already well advanced.
One promising development in early detection involves something as simple as temperature measurement. In a recent study, thermal assessment using an infrared device detected significant differences between rejected and non-rejected grafts as early as one day after surgery, picking up a decrease in graft temperature before any clinical signs were visible. Standard clinical and histological assessments did not flag rejection until day three.6PubMed Central. Thermal Rejection Assessment: New Strategies for Early Detection A temperature drop makes physiological sense: as immune-mediated inflammation disrupts blood flow to the graft, the tissue cools. The simplicity of this approach makes it appealing for routine monitoring.
How Rejection Is Confirmed
Clinical suspicion is the starting point, but definitive diagnosis requires a skin biopsy. Under the microscope, a pathologist looks for immune cells infiltrating the graft tissue and signs of damage to specific structures. In mild rejection of hand allografts, the infiltrate is dominated by CD3+ T cells, with CD8+ cells (the “killer” T cells) being more prominent than CD4+ (“helper”) cells. Adhesion molecules that help immune cells stick to and cross blood vessel walls are upregulated, and these molecular signals tend to increase over time after transplantation.7PubMed. Histopathologic characterization of mild rejection (grade I) in skin biopsies of human hand allografts
A surprising finding from face transplant research has added another layer to the picture. During active rejection, many of the immune cells attacking the graft were found to be donor-origin T cells, specifically the resident memory type that had been living in the transplanted skin all along. These donor T cells were spatially associated with damage to hair follicles, the outer skin layer, and small blood vessels within the graft.8PubMed. Biomarker evaluation of face transplant rejection: association of donor T cells with target cell injury This challenges the conventional assumption that rejection is purely a recipient-versus-donor phenomenon. The transplanted skin carries its own immune cells, and those cells can participate in the damage, making the immunology of skin grafts more complex than a simple attacker-and-target model.
In terms of timing, certain biomarkers shift as the months and years pass. For instance, C4d staining, a marker associated with antibody-mediated rejection, tends to become positive only after the first year following hand transplantation. Regulatory T cells marked by FoxP3, which help suppress immune responses, also shift over time. These evolving patterns mean that a biopsy taken at three months tells a different story than one taken at two years, and pathologists interpret them accordingly.7PubMed. Histopathologic characterization of mild rejection (grade I) in skin biopsies of human hand allografts
Systemic Immunosuppression
The standard approach to preventing and treating rejection in skin allografts relies on systemic immunosuppressive drugs, typically a combination of three medications. This “triple therapy” usually includes a calcineurin inhibitor like tacrolimus, an antiproliferative agent like mycophenolate mofetil, and a corticosteroid. Together, these drugs dampen the immune response enough to keep the graft alive.
The catch is that the standard regimen often needs adjustment. Kidney toxicity from calcineurin inhibitors is a common problem that forces changes. In a comprehensive review of hand and face transplant recipients, the most frequent alternatives included switching to sirolimus (used in about 28 percent of hand transplant patients who needed a change) or everolimus (about 10 percent). For face transplant recipients who needed modifications, photopheresis and sirolimus were the leading alternatives.4PubMed Central. Immunosuppressive strategies in face and hand transplantation: a comprehensive systematic review of current therapy regimens and outcomes Despite these medications, rejection episodes still occurred in about two-thirds of hand transplant patients and nearly three-quarters of face transplant patients. Complete graft loss was reported in about 13 percent of hand transplants and 9 percent of face transplants.
These numbers highlight a difficult reality: immunosuppression reduces rejection but does not eliminate it, and the drugs themselves create health risks. Patients on long-term immunosuppressants face elevated risks of infections, certain cancers, metabolic problems, and organ damage. For someone who received a life-saving burn graft, the calculus is straightforward. For elective composite tissue transplants, the tradeoff between graft survival and drug side effects is one of the hardest conversations in transplant medicine.
Topical Treatments as an Adjunct
Because skin is uniquely accessible compared to internal organs, there is a strong rationale for treating it locally. Topical immunosuppression can deliver high drug concentrations directly to the graft while minimizing the systemic exposure that causes side effects elsewhere in the body.9Plastic and Reconstructive Surgery. Daily Topical Tacrolimus Therapy Prevents Skin Rejection in a Rodent Hind Limb Allograft Model
In clinical practice, topical tacrolimus ointment combined with a potent topical steroid like clobetasol has been used to manage acute rejection episodes in hand transplant recipients. In reported cases, two weeks of topical treatment alongside maintenance systemic drugs resolved the rejection without requiring the pulse-dose intravenous steroids that carry their own risks. Biopsies afterward showed a significant drop in T-cell and B-cell infiltration, along with an increase in regulatory T cells, the immune cells that help prevent overreaction.10PubMed. Topical tacrolimus and steroids modulate T cells in acute rejection of hand allotransplantation: Two case reports The idea of boosting regulatory T cells locally is especially interesting, because it suggests topical therapy may do more than just suppress inflammation; it may actively promote tolerance at the graft site.
Topical therapy is not a replacement for systemic drugs in allografts. It works as an add-on during rejection flares, a way to intensify local treatment without ratcheting up whole-body immunosuppression. For patients who are already dealing with side effects from their systemic regimen, that distinction matters enormously.
When Rejection Is Not the Problem
Most skin grafts performed in everyday clinical settings are autografts, where a patient’s own skin is moved from one body site to another. Burn units, trauma centers, and reconstructive surgeons rely on autografts as their workhorse procedure. Because the tissue carries the patient’s own HLA markers, immune rejection does not occur. The graft still has to survive the critical early window where it establishes a blood supply, initially absorbing nutrients from fluid in the wound bed during the first 48 hours and then connecting to new blood vessels growing up from below.11PubMed Central. Real-Time Demonstration of Split Skin Graft Inosculation and Integra Dermal Matrix Neovascularization Using Confocal Laser Scanning Microscopy
Autograft failure happens for mechanical and vascular reasons, not immunological ones. Infection beneath the graft, movement that shears the fragile new blood vessel connections, or a poorly prepared wound bed can all cause the graft to die. In a large US claims study of patients who received autografts for non-burn full-thickness wounds, regrafting was needed in about 3 to 8 percent of cases depending on the care setting, and outright graft failure occurred in up to 5 percent of inpatient cases.12PubMed. Clinical and Economic Burden of Autologous Skin Grafting for Nonthermal Full-Thickness Wounds Across Care Settings: A US Retrospective Claims Study The costs are substantial even without rejection in the picture: average annual costs per patient reached over $260,000 for those treated as inpatients, reflecting the medical complexity of the wounds that require grafting in the first place.
Bioengineered Skin and the Rejection Question
The appeal of lab-grown or artificial skin substitutes is obvious: if you could replace damaged skin without using donor tissue, you might sidestep the immune system entirely. Various products exist, ranging from acellular scaffolds (frameworks stripped of living cells) to constructs seeded with cells grown in a lab. In theory, removing donor cells should eliminate the foreign proteins that trigger rejection.
In practice, the problem has not been fully solved. Even skin substitutes that have been processed to remove cellular material can still provoke immune responses, possibly because residual proteins or structural components are recognized as foreign. A comprehensive review noted that no skin substitute currently available has entirely overcome the phenomenon of immunological rejection.13PubMed Central. Immunological challenges associated with artificial skin grafts: available solutions and stem cells in future design of synthetic skin Stem-cell-based approaches and more sophisticated tissue engineering are active areas of research, with the goal of creating constructs that integrate seamlessly without awakening the immune system. But for now, engineered skin products function primarily as temporary wound coverings or scaffolds that the patient’s own cells gradually populate, rather than as permanent, rejection-free replacements.
Teaching the Immune System to Accept a Graft
The holy grail in transplantation is tolerance, a state where the recipient’s immune system permanently accepts the donor tissue without ongoing drug suppression. In skin grafting, achieving tolerance is especially difficult precisely because skin is so immunogenic. But animal research has made progress.
One strategy involves creating what is called mixed chimerism: transplanting bone marrow from the donor alongside the skin graft so that the recipient’s immune system contains cells from both individuals. In mouse models, constructing a bone marrow chimera before skin grafting induced donor-specific tolerance. The key mechanism appeared to involve a significant expansion of regulatory T cells in the recipient’s immune compartment, which rose from about 19 percent to 34 percent.14PubMed Central. Role of regulatory T cells in transferable immunological tolerance to bone marrow donor in murine mixed chimerism model Subsequent skin grafts from the same donor strain were accepted without additional immunosuppression. A related approach used retinoic acid to generate donor-specific regulatory T cells before the bone marrow transplant, combined with lower doses of radiation, and also achieved stable mixed chimerism and skin graft tolerance in mice.15PubMed Central. Alloreactive Regulatory T Cells Allow the Generation of Mixed Chimerism and Transplant Tolerance
These results remain in the preclinical stage. Translating bone marrow chimerism protocols to humans involves risks, including the radiation and conditioning needed to make room for the donor marrow. But the principle that regulatory T cells can be harnessed to retrain the immune system is the foundation of several clinical research programs. If tolerance can be reliably achieved, it would eliminate the need for lifelong immunosuppression and all the health costs that come with it.
The Psychological Weight of Graft Complications
Rejection and graft failure are not just medical events. For patients who have already endured significant injuries, the prospect or experience of a failing graft adds another layer of distress. Even in the relatively common case of split-thickness autografts (where rejection is not the issue), psychological outcomes are worth attention. A survey of patients who had undergone split-thickness skin grafting found that 19 percent reported clinically significant anxiety and 13 percent reported depression. More than 10 percent experienced meaningful appearance-related distress compared to general population norms.16PubMed. The psychological impact of split-thickness skin grafts Patients who rated their graft or donor site as more noticeable tended to score higher on both anxiety and depression measures.
For patients living with allografts such as transplanted hands or faces, the psychological stakes are amplified. Rejection episodes are visible, often occurring on parts of the body that are central to identity and social interaction. The need for lifelong immunosuppression adds chronic health anxiety to an already complex emotional picture. Transplant teams increasingly recognize that psychological support is not optional but an integral part of managing graft patients over time, particularly when rejection flares force medication changes or raise the possibility of graft loss.
Scarring Outcomes in Younger Patients
Children who undergo skin grafting face a distinct set of challenges. Pediatric burn patients in particular tend to develop more prominent scars at graft sites, and several factors predict worse outcomes. In a study evaluating scar quality after pediatric skin grafting, younger age at the time of surgery was associated with worse scar scores, with each year younger adding about 0.7 points to a validated scar assessment scale. Longer healing times after surgery also predicted worse scars, with each additional day adding about 0.2 points. Location mattered considerably: grafts on the lower extremities scored about 11 points worse than grafts on the upper extremities, and trunk grafts scored about 8 points worse.17PubMed Central. Evaluating scar outcomes in pediatric burn patients following skin grafting These are not rejection findings per se, but they reflect the broader reality that graft outcomes depend on patient age, wound healing biology, and anatomical location in ways that go well beyond whether the immune system cooperates.